banner2

Getting started
N-Boc-DL-Tryptophan CAS 112525-72-1

N-Boc-DL-Tryptophan CAS 112525-72-1 - Manufacturers, Suppliers, Factory from China

N-Boc-DL-Tryptophan CAS 112525-72-1, , , ,. The product will supply to all over the world, such as Europe, America, Australia,, ,, .

Related Products

N-Boc-DL-Tryptophan CAS 112525-72-1 (Boc-DL-Trp-OH) Factory Shanghai Ruifu Chemical Co., Ltd. www.ruifuchem.com — N-Boc-DL-Tryptophan CAS 112525-72-1 (Boc-DL-Trp-OH) Assay >98.5% (T) (HPLC)
Read More

Z-HomoPhe-OH CAS 127862-89-9 Assay ≥98.0% (HPLC)

Z-Ser-OH CAS 1145-80-8 N-Cbz-L-Serine Assay ≥99.0% (HPLC)

Z-Hyp-OH CAS 13504-85-3 Purity ≥99.0% (HPLC)

N-Cbz-N-Methyl-L-Isoleucine CAS 42417-66-3 Purity ≥98.0% (HPLC)

D-2-Cyanophenylalanine CAS 263396-41-4 Assay ≥98.0% (HPLC)

D-3-Cyanophenylalanine CAS 263396-43-6 Assay ≥98.0% (HPLC)

banner1

Top Selling Products

Related Blog
Reviews

The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) -Shanghai Ruifu Chemical Co., Ltd. will attend with customers.

Shanghai Ruifu Chemical Co., Ltd. will attend the The 87th China International Pharmaceutical Apis/Intermediates/Packaging/Equipment Fair (API China) with customers. The 87th China International ...
Yellow phosphorus and phosphoric acid rose together

Yellow phosphorus and phosphoric acid rose together Yunnan-guizhou yellow phosphorus prices rose.Data show that the offer of 34500 yuan/ton at the beginning of the week has risen to 60,000 yuan/to...
New COVID treatments offer hope

Scientists around the world have made promising breakthroughs in developing a cure for COVID-19. Among new developments include antiviral pills and antibody compounds. As more countries look to ado...
Xi presents award to top scientists

President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, presents China’s top science award to a...
Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study

Friday, November 05, 2021 – 06:45am PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adult...
Focus on Cross Border Integration of Biomedicine and Chemical Materials, October 15, 2021

Focus on Cross Border Integration of Biomedicine and Chemical Materials: New Opportunities, New Technologies and New Models This forum focuses on the interdisciplinary and cutting-edge technologies...

2022.10.28 23:21:35
2022.10.24 21:06:14
2022.06.18 18:54:40
2022.05.12 04:15:49
2022.01.03 05:40:14
2021.12.26 01:52:09

related search